27.34
+0.9(+3.40%)
Currency In HKD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
40557
First IPO Date
October 30, 2012
| Name | Title | Pay | Year Born |
| Mr. Deyong Wen | Joint President, Chief Executive Officer & VC | 0 | 1971 |
| Mr. Wenjie Zhang | Executive President & Co-Chief Executive Officer of Innovative Drug Division | 0 | 1967 |
| Ms. Jing Li | Executive President and Chief Executive Officer of Established Medicines Manufacturing & Supply Division | 0 | 1972 |
| Mr. Wang Xingli M.D., Ph.D. | Executive President, Co-Chief Executive Officer of Innovative Medicines Division and CEO of Global R&D Center | 0 | 1962 |
| Ms. Xiaohui Guan | Executive Co-Chairman | 0 | 1971 |
| Mr. Kexin Wang | Executive Director | 0 | 1965 |
| Mr. Zhanyu Chen | Senior Vice President & Chief Financial Officer | 0 | N/A |
| Mr. Donghua Wang | Senior Vice President & Chief Strategic Enabler | 0 | 1969 |
| Ms. Rongli Feng | Executive President & Chief Human Resources Office | 0 | 1975 |
| Mr. Yuqing Chen | Executive Chairman | 0 | 1975 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.